With Additional Active Ingredient Patents (Class 514/171)
  • Patent number: 10702499
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: July 7, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Patent number: 10695308
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: June 30, 2020
    Assignee: United Therapeutics Corporation
    Inventor: Michael Wade
  • Patent number: 10688041
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles including pharmaceutical agents that have a low water/aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: June 23, 2020
    Assignee: Kala Pharmaceuticals, Inc.
    Inventor: Alexey Popov
  • Patent number: 10682337
    Abstract: Methods for treating and preventing pyrexia and other diseases in equines such as horses involving administering an oral pharmaceutical formulation containing metamizole are disclosed.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: June 16, 2020
    Assignee: Kindred Biosciences, Inc.
    Inventor: Emily Sundman
  • Patent number: 10675288
    Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: June 9, 2020
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
  • Patent number: 10646496
    Abstract: The present invention provides joint use of stain and adrenocortical hormone for preparing a pharmaceutical product for the treatment of chronic subdural hematoma. The pharmaceutical product according to the present invention is capable of accelerating hematoma absorption and improving a therapeutic effect of single oral administration of a statin-based pharmaceutical product, and the dose of the adrenocortical hormone-based pharmaceutical product used is 1/10 of the dose used in a large-dose hormonal therapy.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: May 12, 2020
    Inventors: Jianning Zhang, Rongcai Jiang, Dong Wang
  • Patent number: 10632085
    Abstract: Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5-dihydroxybenzenesulfonic acid are provided. Also provided are methods of treating psoriasis comprising administering crystalline forms of potassium 2,5-dihydroxybenzenesulfonic acid.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: April 28, 2020
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Unni Santhosh, Annadurai Marimuthu Senthilkumar, Bodireddy Mohan Reddy, Rajendran Kamala, Mahender Rao Siripragada
  • Patent number: 10618904
    Abstract: The present invention provides a hydrobromide of methyl 3-[(4s)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazol[1,2-a][1,4]benzodiazepine-4-yl] propionate and its related crystal forms, preparation method and use thereof. The hydrobromide has excellent solubility (>100 mg/ml), which is significantly superior to other currently commercially available or developed salt products, and is especially suitable for the preparation of injections, has relatively good stability in various crystal forms, and has good practical value and market prospects.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: April 14, 2020
    Assignee: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.
    Inventors: Haoxi Huang, Guoqing Zhuo, Guoning Shang, Zhen Liang, Ting Chu, Cuicui Chen, Ming Luo, Yingfu Li, Zhonghai Su
  • Patent number: 10617671
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 14, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Patent number: 10596181
    Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: March 24, 2020
    Assignee: M ET P PHARMA AG
    Inventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
  • Patent number: 10588912
    Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 17, 2020
    Assignee: Havah Therapeutics Pty Ltd
    Inventor: Stephen Nigel Birrell
  • Patent number: 10561672
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: February 18, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • Patent number: 10548862
    Abstract: Provided is a topical formulation for preventing or treating acne, including a benzenesulfonamide derivative, and a pharmaceutically or cosmetically acceptable excipient. Also provided is a method for preventing or treating acne, including applying the topical formulation on skin of a subject in need thereof.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 4, 2020
    Assignees: Gongwin Biopharm Holdings Co., Ltd.
    Inventors: Chuan-Ching Yang, Mao-Yuan Lin, Tai-Jung Wu, Chi-Chiang Tu, Shun-Chi Wu
  • Patent number: 10537585
    Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 21, 2020
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Caterina Kreyenborg, Elisabeth Meimberg, Corinna Tissen, Karl-Heinz Bannefeld, Tomer Gold
  • Patent number: 10500176
    Abstract: The present invention relates to use of a composition comprising D-glyceric acid (DGA), DL-glyceric acid, L-glyceric acid, or hydroxypyruvatic acid and/or their salts or esters. Further, the invention relates to the use of said composition for enhancing direct and indirect mitochondrial metabolism, e.g. the ATP producing electron transport system (ETS), citric acid cycle or tricarboxylic acid cycle, (TCA), and beta oxidation, and also enhancing the shuttling of reducing equivalents from mitochondrial matrix into the cytosol and protein synthesis in the endoplasmic reticulum. Directly related to the above the use of DGA relates also to reducing the formation of reactive oxygen species (ROS). Alleviating, preventing and even healing effects towards extremely wide range of non-communicable diseases materializes.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: December 10, 2019
    Assignee: REPLICON HEALTH OY
    Inventors: Petteri Hirvonen, Peter Eriksson, Risto Kaksonen
  • Patent number: 10487093
    Abstract: This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the compounds in treating bacterial infections and in methods of treating bacterial infections.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: November 26, 2019
    Assignee: Redx Pharma PLC
    Inventors: Ian Cooper, Amanda Lyons, David Orr, James Kirkham, Kevin Blades
  • Patent number: 10463640
    Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: November 5, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Patent number: 10463690
    Abstract: The present invention relates to the use of chlorine dioxide compositions for treating cancerous tumors. The present invention relates to compositions and methods for treating cancerous tumors, including naïve, metastatic and recurrent cancers. The compositions comprise chlorine dioxide in an effective amount, which is injected into the cancerous tumor at least once, and often at least several times over the course of treatment. The chlorine dioxide compositions are injected directly into the cancerous tumor and the resulting tumor is effectively eliminated from the patient or subject over a period of one to several days to a few weeks, often after a single injection, or multiple injections at one session into the tumor. Often, an initial injection or multiple injections at one session are sufficient to dissolve the cancerous tumor. Often the cancer is eliminated (as evidenced by no remission) in a period of no more than several days to about two-three months and does not recur.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 5, 2019
    Inventor: Howard Alliger
  • Patent number: 10463585
    Abstract: A cosmetic composition is provided, the composition comprising a safe and effective amount of a skin care active with A log P less than ?2.0, a safe and effective amount of a fatty alcohol; and a safe and effective amount of a glyceryl ester. The combination of fatty alcohol and glyceryl esters surprisingly enhances penetration of skin care actives with low A log P values into skin.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: November 5, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Kunal Virendra Gujraty, Shikhar Gupta, Yan Yan, Naohisa Yoshimi
  • Patent number: 10456436
    Abstract: The present invention relates to the use of a compound comprising plant based saponins for regulating and balancing gut microflora in a subject. The present invention also relates to the use of a compound comprising plant based saponins for exerting anti-cancer and anti-inflammatory effects by regulating and balancing the gut microbial ecosystem and providing a healthy epithelial microenvironment in the gut for a subject.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 29, 2019
    Inventor: Wen Luan Wendy Hsiao
  • Patent number: 10441596
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 15, 2019
    Assignee: The University of Chicago
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • Patent number: 10441558
    Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: October 15, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Patent number: 10434076
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 8, 2019
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 10420779
    Abstract: The present invention relates to a composition appropriate for topical application, containing fusidic acid. The homogeneity of the fusidic acid is 90% to 110% of the suggested fusidic acid content, and the amount of air present in the cream is lower than 5 vol %. Furthermore, the present invention also relates to a method for preparing the composition. First, a placebo cream and a suspension of fusidic acid are prepared, which are subsequently mixed at a temperature above the melting point of the placebo cream.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: September 24, 2019
    Assignee: Hyloris Pharmaceuticals SA
    Inventor: Thomas Jacobsen
  • Patent number: 10376510
    Abstract: Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 13, 2019
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins
  • Patent number: 10370356
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 6, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, David House, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10357492
    Abstract: The present invention relates to a method of treating motor neuron diseases such as amyotrophic lateral sclerosis (ALS) using levosimendan or its active metabolite (II) as an active ingredient. Levosimendan or its active metabolite (II) are able to relieve the loss of skeletal muscle strength or function associated with motor neuron diseases.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: July 23, 2019
    Assignee: Orion Corporation
    Inventor: Ken Lindstedt
  • Patent number: 10350185
    Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: July 16, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Sadasivan Vidyasagar, Paul Okunieff
  • Patent number: 10335454
    Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 2, 2019
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Anthony Coates, Yanmin Hu
  • Patent number: 10335368
    Abstract: The present invention is directed to compositions and methods for delivering a tissue scaffold comprising ultrasound-triggerable agents to an individual.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: July 2, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mario L. Fabiilli, Christopher Wilson, Frederic Padilla, Francisco Martin-Saavedra
  • Patent number: 10323003
    Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 18, 2019
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
  • Patent number: 10322101
    Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 18, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Patent number: 10300077
    Abstract: The present disclosure is directed to methods, compositions, and kits for treating dementia.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 28, 2019
    Inventor: Steven Hoffman
  • Patent number: 10265329
    Abstract: A method of treating steroid-dependent disease such as prostate cancer in a subject is described that includes administering a therapeutically effective amount a CYP17A inhibitor and an effective amount of a 5-?-reductase inhibitor to the subject.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: April 23, 2019
    Assignees: THE CLEVELAND CLINIC FOUNDATION, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Nima Sharifi, Zhenfei Li, Richard Auchus
  • Patent number: 10258058
    Abstract: A method for preparing functional edible oil rich in phytosterol esters and diglycerides includes steps of: 1) adding a raw material: adding phytosterol, triglyceride and a molecular sieve into a reactor, wherein a ratio of the phytosterol and the triglyceride is 1:2-1:4, a molecular sieve amount is 50 g/L; heating to 50-60° C. and stirring for 30-60 min, for obtaining a pre-mixture; 2) providing non-aqueous enzymatic transesterification: adding 5-20 g/L lipase into the pre-mixture, adding 100-200 ppm antioxidant, stirring and reacting for 8-12 h with a temperature of 50-60° C. and an atmospheric pressure, stopping heating and naturally cooling to a room temperature; and 3) post-treating: after reaction, removing the lipase and the molecular sieve by centrifugation, for obtaining the functional edible oil. The functional edible oil rich in two nutritional active components is obtained by the one-step method. Products of the present invention do not need separation and purification, and operation is simple.
    Type: Grant
    Filed: May 7, 2017
    Date of Patent: April 16, 2019
    Assignee: OIL CROPS RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SECIENCES
    Inventors: Fenghong Huang, Mingming Zheng, Shi Wang, Xia Xiang, Jie Shi, Qianchun Deng, Wenlin Li, Chuyun Wan
  • Patent number: 10251880
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: April 9, 2019
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Patent number: 10245272
    Abstract: A transmembrane penetration enhancer includes a thermotropic liquid crystal suitably prepared for use in a therapeutic system to improve delivery of at least one active ingredient across a biomembrane and/or skin. The thermotropic liquid crystal comprises at least one cholesteryl ester and is effective in a mesomorphic state at a temperature of the biomembrane and/or skin. A therapeutic system includes the prepared thermotropic liquid crystal for enhanced transmembrane penetration and at least one active ingredient for delivery by the thermotropic liquid crystal. A method for making and using the transmembrane penetration enhancer is presented.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: April 2, 2019
    Inventors: Iryna Kravchenko, Sergiy Lozovsky
  • Patent number: 10238637
    Abstract: Modulators of adenosin A3 receptors of formula (I): And procedure for preparing these compounds. Other objectives of the present invention are to provide pharmaceutical compositions comprising an effective amount of these compounds and the use of the compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of the adenosine A3 receptor.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 26, 2019
    Assignee: PALOBIOFARMA, S.L.
    Inventors: Julio Castro-Palomino Lária, Juan Camacho Gómez
  • Patent number: 10195408
    Abstract: Certain embodiments of the invention relates to a transdermal drug delivery system containing donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, more specifically to a transdermal drug delivery system containing a drug-containing matrix layer comprising donepezil or its pharmaceutically acceptable salt, a styrene copolymer, a hydrogenated rosin glycerol ester, and optionally a hydrocarbon resin.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 5, 2019
    Assignee: NAL PHARMACEUTICAL GROUP LIMITED
    Inventors: Y. Joseph Mo, Tiffany Kawai
  • Patent number: 10155005
    Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: December 18, 2018
    Assignee: HAVAH THERAPEUTICS PTY LTD.
    Inventor: Stephen Nigel Birrell
  • Patent number: 10150774
    Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: December 11, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Jun Zhao, Lawrence Wennogle
  • Patent number: 10112918
    Abstract: The invention relates to a derivative of 15-oxospiramilacton, particularly to a compound of Formula I or II, or an isomer, a solvate or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the compound as pharmaceutically active ingredient, a method for preparing the same, and use thereof in manufacture of an anti-tumor agent. The derivative of 15-oxospiramilactone of the invention have an activity against multiple tumor cell lines, and the anti-tumor activity is positively correlated to an activity inhibiting the Wnt signaling pathway.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: October 30, 2018
    Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, The Key Laboratory of Chemistry for Natural Product of Guizhou Province and Chinese Academy of Science, Shanghai Institutes of Biological Sciences, CAS, Institute of Zoology, Chinese Academy of Sciences
    Inventors: Xiaojiang Hao, Chen Yan, Haiyang Liu, Lin Li, Xiaoli He, Quan Chen
  • Patent number: 10092523
    Abstract: The present invention relates to long acting pharmaceutical compositions or pharmaceutically acceptable salts thereof, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: October 9, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventor: Brian Alvin Johns
  • Patent number: 10085973
    Abstract: The present inventor has found out that the following criteria enable to ensure an effect for increasing the platelet count while preventing an excessive increase in the platelet count; “when the platelet count has increased by a certain amount and reached to a sufficient level of the platelet count during administration of a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity, administration of the pharmaceutical composition is discontinued thereafter”.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: October 2, 2018
    Assignee: Shionogi & Co., Ltd.
    Inventors: Takeshi Kano, Takahiro Fukuhara, Takayuki Katsube
  • Patent number: 10080732
    Abstract: A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or a pharmaceutically acceptable salt thereof. Embodiments described herein relate to compositions and methods of stimulating ventilatory and/or respiratory drive in a subject in need thereof, and particularly relates to compositions and methods of treating breathing diseases and/or disorders associated with impaired ventilatory and/or respiratory drive.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: September 25, 2018
    Assignee: Case Western Reserve University
    Inventors: Benjamin Gaston, Stephen Lewis
  • Patent number: 10076505
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: September 18, 2018
    Assignee: United Therapeutics Corporation
    Inventor: Michael Wade
  • Patent number: 10071130
    Abstract: Embodiments of the invention are directed to methods of treating cancer cells, particularly breast cancer cells, such as chemo-resistant cells, with an Hsp90 inhibitor and an anticancer agent or compound such as chemotherapy.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 11, 2018
    Assignee: The University of Chicago
    Inventor: Suzanne D. Conzen
  • Patent number: 10049866
    Abstract: A method for analyzing an aliphatic compound by mass spectrometry which comprises: (i) ionizing an aliphatic compound in the presence of a heterocyclic modifier; and (ii) mass analyzing the resulting ions to obtain mass spectrometric data.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 14, 2018
    Assignee: MICROMASS UK LIMITED
    Inventors: David Douce, Gareth R. Jones
  • Patent number: 10034848
    Abstract: Disclosed herein is a method for increasing the dendritic spine formation or dendritic spine density in a subject, who is affected by a dendritic spine defect caused by the impairment in neurofibromin (NF1 protein), valosin-containing protein (VCP), atlastin-1 (ATL1), or superoxide dismutase 1 (SOD1). Accordingly, also disclosed herein is a method for treating a subject having or suspected of having a synaptopathy caused by the impairment in NF1, VCP, ATL1, or SOD1.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: July 31, 2018
    Assignee: Academia Sinica
    Inventor: Yi-Ping Hsueh
  • Patent number: 10017506
    Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: July 10, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Deping Wang, Zhili Xin, Lei Zhang